Abstract
Virtual screening uses computer-based methods to discover new ligands on the basis of biological structures. Although widely heralded in the 1970s and 1980s, the technique has since struggled to meet its initial promise, and drug discovery remains dominated by empirical screening. Recent successes in predicting new ligands and their receptor-bound structures, and better rates of ligand discovery compared to empirical screening, have re-ignited interest in virtual screening, which is now widely used in drug discovery, albeit on a more limited scale than empirical screening.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
A systematic study of key elements underlying molecular property prediction
Nature Communications Open Access 13 October 2023
-
AI-accelerated protein-ligand docking for SARS-CoV-2 is 100-fold faster with no significant change in detection
Scientific Reports Open Access 06 February 2023
-
Galileo: Three-dimensional searching in large combinatorial fragment spaces on the example of pharmacophores
Journal of Computer-Aided Molecular Design Open Access 24 November 2022
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Beddell, C. R., Goodford, P. J., Norrington, F. E., Wilkinson, S. & Wootton, R. Compounds designed to fit a site of known structure in human haemoglobin. Br. J. Pharmacol. 57, 201–209 (1976).
Cohen, S. S. A strategy for the chemotherapy of infectious disease. Science 197, 431–432 (1977).
Itzstein, M. V. et al. Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature 363, 418–423 (1993).
Varney, M. D. et al. Crystal-structure-based design and synthesis of Benz[cd]indole-containing inhibitors of thymidylate synthase. J. Med. Chem. 35, 663–676 (1992).
Kuntz, I. D. Structure-based strategies for drug design and discovery. Science 257, 1078–1082 (1992).
Jorgensen, W. L. The many roles of computation in drug discovery. Science 303, 1813–1818 (2004).
Stahura, F. L. & Bajorath, J. Virtual screening methods that complement HTS. Comb. Chem. High Throughput Screen 7, 259–269 (2004).
Perutz, M. F. The hemaglobin molecule. Sci. Am. 211, 64–76 (1964).
van Gunsteren, W. F. & Berendsen, H. J. C. Computer simulation of molecular dynamics: methodology, applications, and perspectives in chemistry. Angew. Chem. Int. Ed. Engl. 29, 992–1023 (1990).
Rizzo, R., Wang, D., Tirado-Rives, J. & Jorgensen, W. Validation of a model for the complex of HIV-1 reverse transcriptase with sustiva through computation of resistance profiles. J. Am. Chem. Soc. 122, 12898–12900 (2000).
Rosenfeld, R. J. et al. Automated docking of ligands to an artificial active site: augmenting crystallographic analysis with computer modeling. J. Comput. Aided Mol. Des. 17, 525–536 (2003).
Brik, A. et al. Rapid diversity-oriented synthesis in microtiter plates for in situ screening of HIV protease inhibitors. Chembiochem. 4, 1246–1248 (2003).
Schapira, M. et al. Discovery of diverse thyroid hormone receptor antagonists by high-throughput docking. Proc. Natl Acad. Sci. USA 100, 7354–7359 (2003).
Evers, A. & Klebe, G. Ligand-supported homology modeling of G-protein-coupled receptor sites: models sufficient for successful virtual screening. Angew. Chem. Int. Ed. Engl. 43, 248–251 (2004).
Shoichet, B. K., McGovern, S. L., Wei, B. & Irwin, J. J. Lead discovery using molecular docking. Curr. Opin. Chem. Biol. 6, 439–446 (2002).
Schneidman-Duhovny, D., Nussinov, R. & Wolfson, H. J. Predicting molecular interactions in silico: II. Protein-protein and protein-drug docking. Curr. Med. Chem. 11, 91–107 (2004).
Wyss, P. C. et al. Novel dihydrofolate reductase inhibitors. Structure-based versus diversity-based library design and high-throughput synthesis and screening. J. Med. Chem. 46, 2304–2312 (2003).
Kick, E. K. et al. Structure-based design and combinatorial chemistry yield low nanomolar inhibitors of cathepsin D. Chem. Biol. 4, 297–307 (1997).
Doman, T. N. et al. Molecular docking and high-throughput screening for novel inhibitors of protein tyrosine phosphatase-1B. J. Med. Chem. 45, 2213–2221 (2002).
Paiva, A. M. et al. Inhibitors of dihydrodipicolinate reductase, a key enzyme of the diaminopimelate pathway of Mycobacterium tuberculosis. Biochim. Biophys. Acta. 1545, 67–77 (2001).
Gradler, U. et al. A new target for shigellosis: rational design and crystallographic studies of inhibitors of tRNA-guanine transglycosylase. J. Mol. Biol. 306, 455–467 (2001).
Powers, R. A., Morandi, F. & Shoichet, B. K. Structure-based discovery of a novel, noncovalent inhibitor of AmpC beta-lactamase. Structure (Camb.) 10, 1013–1023 (2002).
Gruneberg, S., Stubbs, M. T. & Klebe, G. Successful virtual screening for novel inhibitors of human carbonic anhydrase: strategy and experimental confirmation. J. Med. Chem. 45, 3588–3602 (2002).
Wei, B. Q., Baase, W. A., Weaver, L. H., Matthews, B. W. & Shoichet, B. K. A model binding site for testing scoring functions in molecular docking. J. Mol. Biol. 322, 339–355 (2002).
Lipinski, C. A., Lombardo, F., Dominy, B. W. & Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 23, 3–25 (1997).
Oprea, T. I. Current trends in lead discovery: are we looking for the appropriate properties? Mol. Divers 5, 199–208 (2002).
McGovern, S. L., Caselli, E., Grigorieff, N. & Shoichet, B. K. A common mechanism underlying promiscuous inhibitors from virtual and high-throughput screening. J. Med. Chem. 45, 1712–1722 (2002).
Krämer, O., Hazemann, I., Podjarny, A. D. & Klebe, G. Virtual screening for inhibitors of human aldose reductase. Proteins 55, 814–823 (2004).
Horn, J. R. & Shoichet, B. K. Allosteric inhibition through core disruption. J. Mol. Biol. 336, 1283–1291 (2004).
Kaiser, J. NIH Gears up for chemical genomics. Science 304, 1728 (2004).
Kalyanaraman, C., Bernacki, K. & Jacobson, M. P. Virtual screening against highly charged active sites: Identifying substrates of alpha-beta barrel enzymes. Biochemistry in the press.
Pieper, U., Eswar, N., Stuart, A. C., Ilyin, V. A. & Sali, A. MODBASE, a database of annotated comparative protein structure models. Nucleic Acids Res. 30, 255–259 (2002).
Acknowledgements
I thank G. Klebe, A. Olson, and W. Jorgensen for contributing figures and comments, and I. D. Kuntz, M. Jacobson, A. Sali, K. Dill and J. Irwin for many insightful conversations. My laboratory's research in docking is supported by NIGMS.
Author information
Authors and Affiliations
Ethics declarations
Competing interests
B. Shoichet is a partner in a company, Blue Dolphin LLC, that conducts inhibitor discovery campaigns for pharmaceutical and biotech companies.
Rights and permissions
About this article
Cite this article
Shoichet, B. Virtual screening of chemical libraries. Nature 432, 862–865 (2004). https://doi.org/10.1038/nature03197
Published:
Issue Date:
DOI: https://doi.org/10.1038/nature03197
This article is cited by
-
AI-accelerated protein-ligand docking for SARS-CoV-2 is 100-fold faster with no significant change in detection
Scientific Reports (2023)
-
A systematic study of key elements underlying molecular property prediction
Nature Communications (2023)
-
Discovery of novel S6K1 inhibitors by an ensemble-based virtual screening method and molecular dynamics simulation
Journal of Molecular Modeling (2023)
-
Galileo: Three-dimensional searching in large combinatorial fragment spaces on the example of pharmacophores
Journal of Computer-Aided Molecular Design (2023)
-
Rational design of FXR agonists: a computational approach for NASH therapy
Molecular Diversity (2023)